Purpose To update the 2006 American Society of Clinical Oncology guideline on the use of
hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical …

Neutropenia and febrile neutropenia (FN) are common complications of myelosuppressive
chemotherapy. This review provides an up-to-date assessment of the patient and cost …

abstract Bloodstream infections (BSI) are among the most frequent complications in
neutropenic cancer patients and, if caused by Gram-negative rods, are associated with high …

Purpose Chemotherapy-induced febrile neutropenia (FN) causes treatment delays and
interruptions and can have fatal consequences. Current guidelines provide …

Febrile neutropenia (FN) is an oncological emergency and serious complication often
resulting from chemotherapy. In patients with a weak or completely suppressed immune …

Chemotherapy-induced neutropenia (CIN) is one of the most common side effects seen in
cancer patients. As an adverse event, it is deemed undesirable since it often constitutes a …

Objectives To evaluate the use of granulocyte colony-stimulating factor (G-CSF) prophylaxis
in US patients with selected metastatic cancers and chemotherapy-induced febrile …

Chemotherapy-induced neutropenia (CIN) has been associated with a risk of infections and
chemotherapy dose reductions and delays. The chemotherapy regimen remains one of the …

Purpose Limited knowledge is available on the incidence of febrile neutropenia (FN) in
intermediate-risk patients and the rationale for use of granulocyte colony-stimulating factor …

Purpose Contrary to the approved indication for pegfilgrastim prophylaxis, some patients
receive it on the same day as the last administration of chemotherapy in clinical practice …